AP NEWS

Investigation Report on China’s Ambroxol Market, 2018-2022 - ResearchAndMarkets.com

November 19, 2018

DUBLIN--(BUSINESS WIRE)--Nov 19, 2018--The “Investigation Report on China’s Ambroxol Market, 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

According to the report, the incidence and case fatality rate of respiratory diseases in China are high in recent years. Following cardiovascular and cerebrovascular diseases and cancers, respiratory diseases rank third among the chronic diseases that cause deaths in China.

Therefore, developing drugs for the treatment of respiratory diseases has become an important part of drug research.

In the case of respiratory infections (respiratory diseases such as chronic bronchitis), a large amount of sputum is produced, which requires the application of expectorants. Respiratory mucus regulators are the main expectorants.

After years of development, third-generation expectorant Ambroxol has become the most common drug in the clinical treatment of respiratory diseases. The chemical constituent of Ambroxol is ambroxol hydrochloride, an active metabolite of Bromhexine. In 1981, Ambroxol (trade name: Mucosolvan) developed by German company Boehringer Ingelheim was launched.

Compared with the first and second generations of expectorants, Ambroxol excels in dissolving mucus. In 1994, Boehringer Ingelheim’s Ambroxol entered China. Afterwards, the generic drugs by Chinese companies also came onto the market.

According to the publisher’s market research, Ambroxol has been growing rapidly since it entered China. From 2005 to 2014, its annual sales value increased from less than CNY 200 million to CNY 1.26 billion, representing a CAGR of 20.9%. From 2015 to 2017, the sales revenue of Ambroxol declined in China. By sales value, Boehringer Ingelheim takes up a market share of about 44%.

The rest market share is captured by Chinese companies, among which the top market players are Changzhou Siyao Pharmaceuticals Co., Ltd., Shenyang Xinma Pharmaceutical Co., Ltd., TIPR Pharmaceutical Responsible Co., Ltd. and Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd. Ambroxol is sold in China in the dosage forms of injections, solutions, syrups, granules, tablets and capsules. Injections dominate the market.

As environmental pollution and population aging intensify, the incidence of respiratory diseases will keep rising, it is expected that Ambroxol will still have some growth potential in China in the next few years.

Key Topics Covered

1 Relevant Concepts of Ambroxol

1.1 Indications for Ambroxol

1.2 Development of Ambroxol in China

1.3 Governmental Approval of Ambroxol in China

2 Sales of Ambroxol in China, 2013-2017

2.1 Sales Value of Ambroxol

2.1.1 Overall Sales Value

2.1.2 Sales Value by Region

2.2 Sales Volume of Ambroxol

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 Sales of Ambroxol by Dosage Form in China, 2013-2017

2.3.1 Tablets

2.3.2 Capsules

2.3.3 Injections

2.3.4 Solutions

2.3.5 Syrups

2.3.6 Granules

3 Analysis on Major Ambroxol Manufacturers in China, 2013-2017

3.1 Analysis on Market Share of Major Ambroxol Manufacturers

3.1.1 Market Share by Sales Value

3.1.2 Market Share by Sales Volume

3.2 Boehringer Ingelheim

3.2.1 Enterprise Profile

3.2.2 Sales of Boehringer Ingelheim’s Ambroxol in China

3.3 Changzhou Siyao Pharmaceuticals Co., Ltd.

3.3.1 Enterprise Profile

3.3.2 Sales of Changzhou Siyao Pharmaceuticals Co., Ltd.’s Ambroxol in China

3.4 Shenyang Xinma Pharmaceutical Co., Ltd.

3.4.1 Enterprise Profile

3.4.2 Sales of Shenyang Xinma Pharmaceutical Co., Ltd.’s Ambroxol in China

3.5 TIPR Pharmaceutical Responsible Co., Ltd.

3.5.1 Enterprise Profile

3.5.2 Sales of TIPR Pharmaceutical Responsible Co., Ltd.’s Ambroxol in China

3.6 Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd.

3.6.1 Enterprise Profile

3.6.2 Sales of Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd.’s Ambroxol in China

4 Prices of Ambroxol in China, 2017-2018

4.1 Boehringer Ingelheim (Mucosolvan)

4.2 Changzhou Siyao Pharmaceuticals Co., Ltd. (Lansu)

4.3 Shenyang Xinma Pharmaceutical Co., Ltd. (Kaishun)

4.4 TIPR Pharmaceutical Responsible Co., Ltd. (Yinuoshu)

4.5 Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd. (Nuoke)

5 Prospect of China’s Ambroxol Market, 2018-2022

5.1 Forecast on Market Size

5.2 Forecast on Market Trend

For more information about this report visit https://www.researchandmarkets.com/research/zcmrlj/investigation?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181119005332/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs

KEYWORD: ASIA PACIFIC CHINA

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 11/19/2018 06:45 AM/DISC: 11/19/2018 06:45 AM

http://www.businesswire.com/news/home/20181119005332/en

AP RADIO
Update hourly